472 related articles for article (PubMed ID: 31127148)
1. Chronic myeloid leukemia stem cells.
Houshmand M; Simonetti G; Circosta P; Gaidano V; Cignetti A; Martinelli G; Saglio G; Gale RP
Leukemia; 2019 Jul; 33(7):1543-1556. PubMed ID: 31127148
[TBL] [Abstract][Full Text] [Related]
2. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
4. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Morotti A; Panuzzo C; Fava C; Saglio G
Expert Opin Biol Ther; 2014 Mar; 14(3):287-99. PubMed ID: 24387320
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
6. Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Chomel JC; Bonnet ML; Sorel N; Sloma I; Bennaceur-Griscelli A; Rea D; Legros L; Marfaing-Koka A; Bourhis JH; Ame S; Guerci-Bresler A; Rousselot P; Turhan AG
Oncotarget; 2016 Jun; 7(23):35293-301. PubMed ID: 27167108
[TBL] [Abstract][Full Text] [Related]
7. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
8. Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Shah M; Bhatia R
Adv Exp Med Biol; 2018; 1100():97-110. PubMed ID: 30411262
[TBL] [Abstract][Full Text] [Related]
9. Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
Cheloni G; Tanturli M; Tusa I; Ho DeSouza N; Shan Y; Gozzini A; Mazurier F; Rovida E; Li S; Dello Sbarba P
Blood; 2017 Aug; 130(5):655-665. PubMed ID: 28576876
[TBL] [Abstract][Full Text] [Related]
10. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
11. The chronic myeloid leukemia stem cell: stemming the tide of persistence.
Holyoake TL; Vetrie D
Blood; 2017 Mar; 129(12):1595-1606. PubMed ID: 28159740
[TBL] [Abstract][Full Text] [Related]
12. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
[TBL] [Abstract][Full Text] [Related]
13. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
14. Leukemia Stem Cells in Chronic Myeloid Leukemia.
Shan Y; DeSouza N; Qiu Q; Li S
Adv Exp Med Biol; 2019; 1143():191-215. PubMed ID: 31338821
[TBL] [Abstract][Full Text] [Related]
15. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
[TBL] [Abstract][Full Text] [Related]
16. Leukemia stem cells: the root of chronic myeloid leukemia.
Zhou H; Xu R
Protein Cell; 2015 Jun; 6(6):403-12. PubMed ID: 25749979
[TBL] [Abstract][Full Text] [Related]
17. Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia.
Baquero P; Dawson A; Helgason GV
FEBS J; 2019 Apr; 286(7):1271-1283. PubMed ID: 30222247
[TBL] [Abstract][Full Text] [Related]
18. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F; Peyron JF; Mary D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
[TBL] [Abstract][Full Text] [Related]
19. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells.
Zhang H; Li S
Protein Cell; 2013 Mar; 4(3):186-96. PubMed ID: 23483480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]